News and Announcements
$10 Million Institutional Placement to Drive OncoSil Commercialisation
- Published February 03, 2016 2:41PM UTC
- Publisher Wholesale Investor
- Categories Company Updates
3rd February 2016, ASX Announcement
OncoSil Medical Limited (ASX: OSL) (OncoSil Medical, the Company) is pleased to announce a A$10 million Institutional Placement (Placement) to drive commercialisation of the Company’s lead product candidate, the OncoSilTM localised radiation treatment for cancer.
The Placement is by way of Subscription Agreement for approximately 45,454,545 new Ordinary Shares in OncoSil Medical at a price of A$0.22 per share to raise $10 million.
The Company is delighted to receive this level of investment and financial backing at this point and time, and views it as strong validation for the OncoSilTM brachytherapy technology and its global commercialisation potential.
The Placement funds will be used to aggressively drive OncoSil Medical’s commercialisation plans to position OncoSilTM as an innovative, new medical radiation treatment for pancreatic cancer and other solid tumours – which have major un-met medical needs.
To read the full announcement, please click here.
Company Updates
Capital Is Flowing – Just Not to Everyone: Inside Australia’s $1.8 Billion Q1 2026
Australia’s startup ecosystem opened 2026 with a number that demanded attention. In the first three months of the year, $1.8 billion was raised across 81 venture deals and 26 accelerator rounds. That makes Q1 2026 the strongest start to a year since the 2022 boom, up 63% on Q1 2025, and more than double the […]
The control layer for the electrified home
THE MARKET SHIFT Australian households have been pulled into a real-time energy market they never knowingly signed up for. Flat electricity tariffs are disappearing. In their place: dynamic, time-of-use pricing that changes depending on when power is consumed. Electricity is now cheapest when solar floods the grid in the middle of the day — and […]
500 Million Episodes, Limited Treatment: How Patrys is Bridging the Gap in an Underserved Market
In the clinical vocabulary of the Intensive Care Unit, there is perhaps no word that carries as much quiet dread as delirium. It is a “chemical storm” of the brain—an acute dysfunction where the delicate balance between calming and activating signals is scrambled. For the patient, it can be a waking nightmare of hallucinations and […]
Backed By Leading Investment Groups and Family Offices
